Boston Scientific Promotes Joe Fitzgerald to COO and Names New CAO

Executive Leadership Transitions and Compensation Updates

Boston Scientific Corporation reported multiple executive leadership changes and an organizational structure realignment pursuant to Item 5.02 and Item 8.01 of Form 8-K.

1. Promotion of Chief Operating Officer

• Executive: Joseph M. Fitzgerald, age 63, currently serving as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer, effective January 1, 2027.
• Background: Joined Boston Scientific in 1990 and has held senior leadership roles overseeing Cardiology, Interventional Cardiology, and Cardiac Rhythm Management.
• Compensation Terms:
  • Base Salary: $1,050,000 annually (effective January 1, 2027).
  • Annual Bonus Plan: Target incentive percentage increased from 90% to 110% of base salary.
  • Deferred Bonus Plan: Continued eligibility to defer up to 75% of annual bonus awards.
  • Equity Award: 2027 long-term incentive award with an aggregate grant date fair value of $7,000,000 (expected in February 2027), comprising performance-based RSUs, standard RSUs, and stock options vesting at 25% per year.
  • Retirement & Severance: Retains coverage under the Executive Retirement Plan (up to 36 months' base salary) and the standard Change in Control Agreement (2x base salary plus target incentive bonus upon qualifying termination).

2. Chief Accounting Officer Succession

• New CAO: Mark Bickel, age 49, currently SVP, Finance and Global Controller of Cardiovascular, will become Senior Vice President, Global Accounting Controller and Chief Accounting Officer, effective March 1, 2027.
• Outgoing CAO: Emily Woodworth (Collins) will transition from Chief Accounting Officer to Senior Vice President, Global Finance Controller and Finance Transformation, effective March 1, 2027. The filing confirms no disagreements with the company on any accounting principles, practices, or financial disclosures.

3. Organizational Realignment

Concurrent with the COO appointment, Boston Scientific announced the establishment of three reportable segments effective January 1, 2027: Interventional Therapies, Rhythm Solutions, and MedSurg.